Optogenetics for RP: 126-Week Data

David S. Liao, MD, PhD

Show Description +

Dr. Liao showcases the latest extended efficacy and safety data from the RESTORE follow-up study of MCO-010 (Nanoscope Therapeutics) for the treatment of retinitis pigmentosa.

Posted: 8/06/2025

Keywords:

retina-meeting-recap

•

optogenetics

•

Retinitis pigmentosa

•

Clinical Trials

•

RESTORE

•

Nanoscope Therapeutics

Up Next

Name: Optogenetics for RP: 126-Week Data
Uploaded: 2025-08-06T19:48:39+00:00
Description: Dr. Liao showcases the latest extended efficacy and safety data from the RESTORE follow-up study of MCO-010 (Nanoscope Therapeutics) for the treatment of retinitis pigmentosa.

ILM Flaps: 10 Years of Data

Zofia A. Nawrocka, MD, PhD

When to Treat with Pegcetacoplan

Roger A. Goldberg, MD, MBA

Treatment Burden: EYP-1901 Versus Aflibercept

Avni P. Finn, MD, MBA

Pharmacodynamics of ABBV-RGX-314

Robert L. Avery, MD

The PDS Versus Anti-VEGF Injections in the Fellow Eye

Jordan Graff, MD, FACS

UBX1325 For DME: Phase 2 Data

Dante Pieramici, MD

Switching Agents in DME

Michael Javaheri, MD

Treating Underrepresented Patients With DME

Andres Emanuelli, MD

Treating DR with OTX-TKI

Katherine E. Talcott, MD

An Oral Option for Stargardt Disease: New Data

Kenneth C. Fan, MD, MBA

Back to All Videos

Optogenetics for RP: 126-Week Data

David S. Liao, MD, PhD

Dr. Liao showcases the latest extended efficacy and safety data from the RESTORE follow-up study of MCO-010 (Nanoscope Therapeutics) for the treatment of retinitis pigmentosa.

Posted: 8/06/2025

Keywords:

retina-meeting-recap

•

optogenetics

•

Retinitis pigmentosa

•

Clinical Trials

•

RESTORE

•

Nanoscope Therapeutics

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

Optogenetics for RP: 126-Week Data

Up Next

Optogenetics for RP: 126-Week Data

More From ASRS: 2025 Coverage